Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.
about
Chapter 7: PharmacogenomicsMechanisms of drug resistance in colon cancer and its therapeutic strategiesCancer drug resistance: redox resetting renders a wayPharmacologic resistance in colorectal cancer: a reviewTherapies targeting cancer stem cells: Current trends and future challengesAntibody-drug conjugates as novel anti-cancer chemotherapeuticsThe Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer DrugsWhere is it and How Does it Get There - Intracellular Localization and Traffic of P-glycoproteinNuclear export of proteins and drug resistance in cancerCan nanomedicines kill cancer stem cells?Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive systemBlood brain barrier: a challenge for effectual therapy of brain tumorsPluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiersMolecular Mimics of Classic P-Glycoprotein Inhibitors as Multidrug Resistance Suppressors and Their Synergistic Effect on PaclitaxelSpecific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavirStereoselective property of 20(S)-protopanaxadiol ocotillol type epimers affects its absorption and also the inhibition of P-glycoproteinA new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cellsThe reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cellsLocalized Down-regulation of P-glycoprotein by Focused Ultrasound and Microbubbles induced Blood-Brain Barrier Disruption in Rat Brain.Photoacoustic "nanobombs" fight against undesirable vesicular compartmentalization of anticancer drugsPhospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.Therapeutic strategies to improve drug delivery across the blood-brain barrier.Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers.Molecular cloning and characterization of an ABC multidrug efflux pump, VcaM, in Non-O1 Vibrio choleraeSmall-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent.Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism.Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.Functional Expression of P-glycoprotein and Organic Anion Transporting Polypeptides at the Blood-Brain Barrier: Understanding Transport Mechanisms for Improved CNS Drug Delivery?Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors.Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrinThe co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer.Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.Pluronics and MDR reversal: an update.ABC transporters are involved in defense against permethrin insecticide in the malaria vector Anopheles stephensi.HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.
P2860
Q21563496-09D9E79D-2841-4C71-9180-980E7F026784Q26738528-A40FA0BC-2978-40E7-911F-FA36AA20E064Q26750753-5D25114B-77BE-461C-8D5D-3969FB48562DQ26769850-5DF163C2-0C92-4FE9-A0E8-D247CB301B98Q26777880-68A47391-D253-4462-8885-4B6D8495C5D1Q26800175-39EDA679-A685-40DA-86BD-457E88D80A24Q26801532-306C7692-C417-4541-9AAB-A74A1C599C85Q27008624-1DBA036A-A9B7-41D5-9084-0861A3462462Q27012444-B4B2A754-5463-4820-A739-46AB1B8F8713Q27022017-C31F1B5C-A5AE-401A-A90A-1E093FCD39D8Q27690256-00FF3FFE-CEBA-45D9-83F5-1347B5A27817Q28079367-350099FA-F01F-4AE7-AD4D-1363513A0775Q28081947-4A01B2E0-A7E0-46EC-8BC7-3A2C1122B602Q28282826-53A5E7E6-79E5-4470-B492-E96C3CB41D4AQ28469350-D1AF3565-6E23-44B0-9FFD-DD90B39738F5Q28534049-C24D4D49-6EF9-4EDC-953A-4F129852AD8CQ28539251-C46DCC02-F4DC-4C6A-B95D-E2CEFE0EC520Q28541630-57C310A7-D26E-498F-985E-7B6E4CC3A64DQ28544747-E3F82BFC-818E-45BB-93F7-16A75F55CE9CQ30376238-F4A413AF-4892-4089-A749-D9C8E9B44561Q30399655-19C0DED1-A439-4B7C-B27C-FD93289A2792Q30403731-D9EDCAC3-65AF-4C5B-8929-33CD73F95938Q30407443-0F0E0EE2-CEEF-4AB5-A44D-8F76BE35B52CQ30475533-5C3CA09E-DE32-4594-87D4-71C6803BC903Q33187852-ADFBF932-04F4-4500-A4E0-BE67E0DEF6FFQ33490314-D5C5504A-4E96-41CD-B961-FF9D2B8D9D00Q33559358-326CDA2A-6CB7-4FF4-84F3-2CE59A23DD53Q33638100-56AD6F11-1F9D-482E-8B0A-3240E4105E3FQ33703811-0C8535C1-3992-4FBD-B7AC-A508F4895B6FQ33761564-5590AD08-3FE7-4E3A-B655-FCD52F71446BQ33850064-8863FE7C-94AE-4CF8-B5FB-73BB80010BBBQ33893813-D1FE37ED-8A35-460E-8DA0-3C1BAE1C58BEQ33933907-D4E86F9F-3995-4E3C-ACA2-C4A32A9BC251Q33947942-78926CD7-A347-4E3E-95E5-6300A26B4113Q33961526-50D06B9B-6F17-4994-829B-312CAE679B9DQ33982601-C4D246D4-0F5E-4A51-987C-A1494D2A884AQ33985133-6C852279-6CC5-4858-8799-DEF8A1EA3196Q34005678-6399E8DB-BE5F-457E-911F-7D1668C86787Q34012082-A1567D0E-67A4-40C2-8ADC-07A93C606657Q34118293-5EB876B7-B529-4B81-A8C9-3DF8018CAD23
P2860
Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Overcoming multidrug resistanc ...... of inhibiting p-glycoprotein.
@ast
Overcoming multidrug resistanc ...... of inhibiting p-glycoprotein.
@en
type
label
Overcoming multidrug resistanc ...... of inhibiting p-glycoprotein.
@ast
Overcoming multidrug resistanc ...... of inhibiting p-glycoprotein.
@en
prefLabel
Overcoming multidrug resistanc ...... of inhibiting p-glycoprotein.
@ast
Overcoming multidrug resistanc ...... of inhibiting p-glycoprotein.
@en
P2860
P1433
P1476
Overcoming multidrug resistanc ...... of inhibiting p-glycoprotein.
@en
P2093
Helen M Coley
Hilary Thomas
P2860
P304
P356
10.1177/107327480301000207
P577
2003-03-01T00:00:00Z